{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T13:10:18Z","timestamp":1779369018853,"version":"3.53.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Fresenius Kabi Espa\u00f1a SAU"},{"DOI":"10.13039\/501100003086","name":"Eusko Jaurlaritza","doi-asserted-by":"publisher","award":["2020111061\/2023222006"],"award-info":[{"award-number":["2020111061\/2023222006"]}],"id":[{"id":"10.13039\/501100003086","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s41669-026-00642-1","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T17:44:39Z","timestamp":1773078279000},"page":"557-566","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn\u2019s Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned?"],"prefix":"10.1007","volume":"10","author":[{"given":"Iago","family":"Rodr\u00edguez-Lago","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Ignacio","family":"Peinado-Fabregat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Guigini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Cerezales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5986-7158","authenticated-orcid":false,"given":"Francisco","family":"Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Barreiro-de Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"issue":"1","key":"642_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-020-0156-2","volume":"6","author":"G Roda","year":"2020","unstructured":"Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, et al. Crohn\u2019s disease. Nat Rev Dis Primers. 2020;6(1):1\u201319. https:\/\/doi.org\/10.1038\/s41572-020-0156-2.","journal-title":"Nat Rev Dis Primers"},{"key":"642_CR2","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/J.CGH.2020.10.039","volume":"19","author":"L Tsai","year":"2020","unstructured":"Tsai L, Ma C, Dulai PS, Prokop LJ, Eisenstein S, Ramamoorthy SL, et al. Contemporary risk of surgery in patients with ulcerative colitis and Crohn\u2019s disease: a meta-analysis of population-based cohorts. Clin Gastroenterol Hepatol Internet. 2020;19:2031. https:\/\/doi.org\/10.1016\/J.CGH.2020.10.039.","journal-title":"Clin Gastroenterol Hepatol Internet."},{"key":"642_CR3","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1007\/S12325-023-02473-6\/TABLES\/7","volume":"40","author":"M Barreiro-de Acosta","year":"2023","unstructured":"Barreiro-de Acosta M, Molero A, Artime E, D\u00edaz-Cerezo S, Liz\u00e1n L, de Paz HD, et al. Epidemiological, clinical, patient-reported and economic burden of inflammatory bowel disease (Ulcerative colitis and Crohn\u2019s disease) in Spain: a systematic review. Adv Ther [Internet]. 2023;40:1975\u20132014. https:\/\/doi.org\/10.1007\/S12325-023-02473-6\/TABLES\/7.","journal-title":"Adv Ther [Internet]"},{"key":"642_CR4","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/J.DLD.2023.04.010","volume":"55","author":"L Degli Esposti","year":"2023","unstructured":"Degli Esposti L, Daperno M, Dovizio M, Franchi A, Sangiorgi D, Savarino EV, et al. A retrospective analysis of treatment patterns, drug discontinuation and healthcare costs in Crohn\u2019s disease patients treated with biologics. Dig Liver Dis. 2023;55:1214\u201320. https:\/\/doi.org\/10.1016\/J.DLD.2023.04.010.","journal-title":"Dig Liver Dis"},{"key":"642_CR5","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/APT.17675","volume":"58","author":"\u00c5H Everhov","year":"2023","unstructured":"Everhov \u00c5H, S\u00f6derling J, Befrits G, Khalili H, Br\u00f6ms G, Neovius M, et al. Increasing healthcare costs in inflammatory bowel disease 2007\u20132020 in Sweden. Aliment Pharmacol Ther. 2023;58:692\u2013703. https:\/\/doi.org\/10.1111\/APT.17675.","journal-title":"Aliment Pharmacol Ther"},{"key":"642_CR6","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","volume":"70","author":"WR Best","year":"1976","unstructured":"Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn\u2019s Disease Activity Index: National Cooperative Crohn\u2019s Disease Study. Gastroenterology. 1976;70:439\u201344. https:\/\/doi.org\/10.1016\/S0016-5085(76)80163-1.","journal-title":"Gastroenterology"},{"issue":"1","key":"642_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ECCO-JCC\/JJZ180","volume":"14","author":"J Torres","year":"2020","unstructured":"Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment. J Crohns Colitis. 2020;14(1):4\u201322. https:\/\/doi.org\/10.1093\/ECCO-JCC\/JJZ180.","journal-title":"J Crohns Colitis"},{"key":"642_CR8","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/ECCO-JCC\/JJAE091","volume":"18","author":"H Gordon","year":"2024","unstructured":"Gordon H, Minozzi S, Kopylov U, Verstockt B, Chaparro M, Buskens C, et al. ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment. J Crohns Colitis. 2024;18:1531\u201355. https:\/\/doi.org\/10.1093\/ECCO-JCC\/JJAE091.","journal-title":"J Crohns Colitis"},{"key":"642_CR9","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1093\/IBD\/IZAC160","volume":"29","author":"Y Bouhnik","year":"2023","unstructured":"Bouhnik Y, Atreya R, Casey D, G\u00f3recki M, Baik D, Yoon SW, et al. Cost-effectiveness analysis of subcutaneous infliximab for inflammatory bowel diseases in sequential biologic treatment. Inflamm Bowel Dis. 2023;29:898\u2013913. https:\/\/doi.org\/10.1093\/IBD\/IZAC160.","journal-title":"Inflamm Bowel Dis"},{"key":"642_CR10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","volume":"70","author":"W Best","year":"1976","unstructured":"Best W, Becktel J, Singleton J, Kern JF. Development of a Crohn\u2019s disease activity index. National Cooperative Crohn\u2019s Disease Study. Gastroenterology. 1976;70:439\u201344.","journal-title":"Gastroenterology"},{"key":"642_CR11","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.3390\/JCM10132885\/S1","volume":"10","author":"M Chaparro","year":"2021","unstructured":"Chaparro M, Garre A, N\u00fa\u00f1ez Ortiz A, Diz-Lois Palomares MT, Rodr\u00edguez C, Riestra S, et al. Incidence, clinical characteristics and management of inflammatory bowel disease in Spain: large-scale epidemiological study. J Clin Med [Internet]. 2021;10:2885. https:\/\/doi.org\/10.3390\/JCM10132885\/S1.","journal-title":"J Clin Med [Internet]"},{"key":"642_CR12","doi-asserted-by":"publisher","first-page":"i1112","DOI":"10.1093\/ECCO-JCC\/JJAD212.0699","volume":"18","author":"MJ Garc\u00eda","year":"2024","unstructured":"Garc\u00eda MJ, Brenes Y, Vicu\u00f1a M, Bermejo F, Sierra-Aus\u00edn M, Polo Cuadro C, et al. P569 persistence and safety of upadacitinib in Crohn\u2019s disease and ulcerative colitis in real life: results from a Spanish nationwide study. J Crohns Colitis. 2024;18:i1112\u20133. https:\/\/doi.org\/10.1093\/ECCO-JCC\/JJAD212.0699.","journal-title":"J Crohns Colitis"},{"key":"642_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/J.CGH.2024.04.016","author":"M Fumery","year":"2024","unstructured":"Fumery M, Caron B, H\u00e9buterne X, Altwegg R, Roblin X, Stefanescu C, et al. Long-term outcome of risankizumab in Crohn\u2019s disease: a real-world GETAID study. Clin Gastroenterol Hepatol. 2024. https:\/\/doi.org\/10.1016\/J.CGH.2024.04.016.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"642_CR14","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMOA1602773\/SUPPL_FILE\/NEJMOA1602773_DISCLOSURES.PDF","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med [Internet]. 2016;375:1946\u201360. https:\/\/doi.org\/10.1056\/NEJMOA1602773\/SUPPL_FILE\/NEJMOA1602773_DISCLOSURES.PDF.","journal-title":"N Engl J Med [Internet]"},{"issue":"6","key":"642_CR15","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/APT.15958","volume":"52","author":"M Iborra","year":"2020","unstructured":"Iborra M, Beltr\u00e1n B, Fern\u00e1ndez-Clotet A, Iglesias-Flores E, Navarro P, Rivero M, et al. Real-world long-term effectiveness of ustekinumab in Crohn\u2019s disease: results from the ENEIDA registry. Aliment Pharmacol Ther. 2020;52(6):1017\u201330. https:\/\/doi.org\/10.1111\/APT.15958.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"642_CR16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1136\/GUTJNL-2022-328052","volume":"72","author":"B Barberio","year":"2023","unstructured":"Barberio B, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn\u2019s disease: systematic review and network meta-analysis. Gut. 2023;72(2):264\u201374. https:\/\/doi.org\/10.1136\/GUTJNL-2022-328052.","journal-title":"Gut"},{"issue":"1","key":"642_CR17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/J.GASTRO.2006.11.041","volume":"132","author":"JF Colombel","year":"2007","unstructured":"Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial. Gastroenterology. 2007;132(1):52\u201365. https:\/\/doi.org\/10.1053\/J.GASTRO.2006.11.041.","journal-title":"Gastroenterology"},{"key":"642_CR18","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(02)08512-4.","journal-title":"Lancet"},{"key":"642_CR19","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","volume":"399","author":"M Ferrante","year":"2022","unstructured":"Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022;399:2031\u201346. https:\/\/doi.org\/10.1016\/S0140-6736(22)00466-4.","journal-title":"Lancet"},{"key":"642_CR20","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMOA2212728\/SUPPL_FILE\/NEJMOA2212728_DATA-SHARING.PDF","volume":"388","author":"EV Loftus","year":"2023","unstructured":"Loftus EV, Pan\u00e9s J, Lacerda AP, Peyrin-Biroulet L, D\u2019Haens G, Panaccione R, et al. Upadacitinib induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2023;388:1966\u201380. https:\/\/doi.org\/10.1056\/NEJMOA2212728\/SUPPL_FILE\/NEJMOA2212728_DATA-SHARING.PDF.","journal-title":"N Engl J Med"},{"issue":"8","key":"642_CR21","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMOA1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel J-F, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2013;369(8):711\u201321. https:\/\/doi.org\/10.1056\/NEJMOA1215739.","journal-title":"N Engl J Med"},{"key":"642_CR22","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/ECCO-JCC\/JJAC156","volume":"17","author":"B Follin-Arbelet","year":"2022","unstructured":"Follin-Arbelet B, Cvancarova Sm\u00e5stuen M, Hovde \u00d8, Jelsness-J\u00f8rgensen LP, Moum B. Mortality in patients with inflammatory bowel disease: results from 30 years of follow-up in a Norwegian inception cohort (the IBSEN study). J Crohns Colitis. 2022;17:497. https:\/\/doi.org\/10.1093\/ECCO-JCC\/JJAC156.","journal-title":"J Crohns Colitis"},{"key":"642_CR23","unstructured":"Tablas de mortalidad. Resultados nacionales, por comunidades aut\u00f3nomas y provincias. [Internet]. Madrid; 2024. https:\/\/www.ine.es\/dyngs\/INEbase\/es\/operacion.htm?c=Estadistica_C&cid=1254736177004&menu=resultados&idp=1254735573002. Accessed 14 Jan 2026"},{"key":"642_CR24","unstructured":"Instituto Nacional de Estad\u00edstica. C\u00e1lculo de variaciones del \u00cdndice de Precios de Consumo (IPC) [Internet]. 2024 [cited 2024 Feb 2]. https:\/\/www.ine.es\/calcula\/. Accessed 2 Feb 2024"},{"key":"642_CR25","unstructured":"European Medicines Agency. Skyrizi (risankizumab): EPAR-Product Information. Annex I: summary of product characteristics [Internet]. Amsterdam; 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/skyrizi-epar-product-information_es.pdf. Accessed 7 Jan 2025"},{"key":"642_CR26","unstructured":"European Medicines Agency. Stelara (ustekinumab): EPAR-Product Information. Annex I: summary of product characteristics [Internet]. Amsterdam; 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/stelara-epar-product-information_es.pdf. Accessed 7 Jan 2025"},{"key":"642_CR27","unstructured":"European Medicines Agency. Rinvoq (upadacitinib): EPAR-Product Information. Annex I: summary of product characteristics [Internet]. Amsterdam; 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rinvoq-epar-product-information_es.pdf. Accessed 7 Jan 2025"},{"key":"642_CR28","unstructured":"European Medicines Agency. Entyvio (vedolizumab): EPAR-Product Information. Annex I: summary of product characteristics [Internet]. Amsterdam; 2018. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/entyvio-epar-product-information_es.pdf. Accessed 7 Jan 2025."},{"key":"642_CR29","unstructured":"European Medicines Agency. Remicade (infliximab): EPAR-Product Information. Annex I: summary of product characteristics [Internet]. Amsterdam; 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/remicade-epar-product-information_es.pdf. Accessed 7 Jan 2025."},{"key":"642_CR30","unstructured":"European Medicines Agency. Humira (adalimumab): EPAR-Product Information. Annex I: summary of product characteristics [Internet]. Amsterdam; 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/humira-epar-product-information_es.pdf. Accessed 7 Jan 2025."},{"key":"642_CR31","unstructured":"Consejo General de Colegios Oficiales de Farmac\u00e9uticos. Bot PLUS Web (Base de datos de medicamentos) [Internet]. 2024 [cited 2024 Oct 7]. https:\/\/botplusweb.portalfarma.com\/. Accessed 7 Oct 2024."},{"key":"642_CR32","unstructured":"Valc\u00e1rcel-Nazco C, Rodriguez-D\u00edaz B, Guirado-Fuentes C, Garc\u00eda-P\u00e9rez L, stupi\u00f1an-Romero F. CONCEPT-COSTS. Compendium of Healthcare Costs in Spain (CONCEPT-COSTS Database) [Internet]. 2024 [cited 2024 Nov 8]. https:\/\/zenodo.org\/records\/11387757. Accessed 8 Nov 2024."},{"key":"642_CR33","unstructured":"Ministerio de Sanidad. Registro de Actividad de Atenci\u00f3n Especializada (RAE-CMBD) [Internet]. Portal Estad\u00edstico del SNS. 2024 [cited 2024 Nov 5]. https:\/\/www.sanidad.gob.es\/estadEstudios\/estadisticas\/cmbd.htm. Accessed 5 Nov 2024."},{"issue":"1","key":"642_CR34","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/S40273-024-01441-4","volume":"43","author":"L Vallejo-Torres","year":"2025","unstructured":"Vallejo-Torres L. Estimating the incremental cost per QALY produced by the Spanish NHS: a fixed-effect econometric approach. Pharmacoeconomics. 2025;43(1):109\u201322. https:\/\/doi.org\/10.1007\/S40273-024-01441-4.","journal-title":"Pharmacoeconomics"},{"key":"642_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/J.JVAL.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25:3\u20139. https:\/\/doi.org\/10.1016\/J.JVAL.2021.11.1351.","journal-title":"Value Health"},{"issue":"1","key":"642_CR36","doi-asserted-by":"publisher","first-page":"96","DOI":"10.36469\/9791","volume":"6","author":"S Perera","year":"2018","unstructured":"Perera S, Yang S, Stott-Miller M, Brady J. Analysis of healthcare resource utilization and costs after the initiation of biologic treatment in patients with ulcerative colitis and Crohn\u2019s disease. J Health Econ Outcomes Res. 2018;6(1):96\u2013112. https:\/\/doi.org\/10.36469\/9791.","journal-title":"J Health Econ Outcomes Res"},{"issue":"1","key":"642_CR37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/APT.13847","volume":"45","author":"EJ Mao","year":"2017","unstructured":"Mao EJ, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn\u2019s disease and ulcerative colitis. Aliment Pharmacol Ther. 2017;45(1):3\u201313. https:\/\/doi.org\/10.1111\/APT.13847.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"642_CR38","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","volume":"9","author":"NM Noor","year":"2024","unstructured":"Noor NM, Lee JC, Bond S, Dowling F, Brezina B, Patel KV, et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn\u2019s disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol. 2024;9(5):415\u201327. https:\/\/doi.org\/10.1016\/S2468-1253(24)00034-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"642_CR39","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/j.cgh.2020.08.021","volume":"19","author":"FI Scott","year":"2021","unstructured":"Scott FI, Hans AK, Gerich ME, Fennimore B, Mamtani R, Vajravelu RK, et al. Identification of the most effective position for ustekinumab in treatment algorithms for Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2021;19:2082-2092.e10. https:\/\/doi.org\/10.1016\/j.cgh.2020.08.021.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"642_CR40","unstructured":"Mart\u00ednez-Sesmero JM, Crespo-Diz C, Cerezales M, Crespo C, Guigini MA, Schoenenberger-Arnaiz JA. Cost-effectiveness analysis of adalimumab in patients with immune-mediated inflammatory diseases in Spain. OFIL ILAPHAR [Internet]. 2023; First online. https:\/\/www.ilaphar.org\/cost-effectiveness-analysis-of-adalimumab-in-patients-with-immunemediated-inflammatory-diseases-in-spain\/."},{"key":"642_CR41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40265-020-01256-5","volume":"80","author":"H Kim","year":"2020","unstructured":"Kim H, Alten R, Avedano L, Dignass A, Gomoll\u00f3n F, Greveson K, et al. The future of biosimilars: maximizing benefits across immune-mediated inflammatory diseases. Drugs. 2020;80:99\u2013113. https:\/\/doi.org\/10.1007\/s40265-020-01256-5.","journal-title":"Drugs"}],"updated-by":[{"DOI":"10.1007\/s41669-026-00648-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000}}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00642-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-026-00642-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00642-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T12:57:15Z","timestamp":1779368235000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-026-00642-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["642"],"URL":"https:\/\/doi.org\/10.1007\/s41669-026-00642-1","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: the name of the author Manuel Barreiro-de Acosta was incorrectly given as just \u2018Barreiro-de Acosta\u2019.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s41669-026-00648-9","URL":"https:\/\/doi.org\/10.1007\/s41669-026-00648-9","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study concept and design: JIPF, MG, MC, CC. Statistical analysis: FI, CC. Data interpretation: MC, FI, CC. Drafting of the manuscript: MC, FI. Critical revision of the manuscript for important intellectual content: IRL, JIPF, MG, CC, MBA. Study supervision: JIPF, MG, CC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"IRL has received financial support for traveling and educational activities from or has served as an advisory board member for Abbvie, Adacyte, Alfasigma, Biogen, Chiesi, Faes Farma, Ferring, Fresenius Kabi, Galapagos, Johnson & Johnson, Eli Lilly, Mirum Pharmaceuticals, Merck, Pfizer, Roche, Takeda, and Tillotts Pharma. Research support from AbbVie. MBA has been speaker, consultant and advisory member for or has received research funding from MSD, AbbVie, Janssen, Kern Pharma, Celltrion, Takeda, Alphasigma, Lilly, Pfizer, Sandoz, Biocon, Abivax, Fresenius, Faes Farma, Ferring, Tillots, Chiesi, Adacyte, Diasorin, Oncostellae and SunRock. JIPF and MG are employees of Fresenius Kabi Espa\u00f1a. MC, FI, and CC are employees of Axentiva Solutions S.L., a consultancy firm that works for several pharmaceutical and medical devices companies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The model code is proprietary and subject to intellectual property restrictions; therefore, it is not available for public distribution. Access was provided to the editors and reviewers solely for the peer-review process.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}